Exemestane Tablet
Product Images NDC 69097-316

4 FDA label images from Cipla Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Exemestane (NDC 69097-316). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Edfb31df 8ec2 440f 84ca 5e86c10bbc46 01

Edfb31df 8ec2 440f 84ca 5e86c10bbc46 01
Chemical structure of exemestane, a steroidal aromatase inhibitor. The diagram shows the molecular framework with characteristic rings, carbon, and oxygen atoms as part of the exemestane molecule.*
FDA Label Image

Edfb31df 8ec2 440f 84ca 5e86c10bbc46 02

Edfb31df 8ec2 440f 84ca 5e86c10bbc46 02
A Kaplan-Meier survival curve comparing disease-free survival between patients treated with exemestane and tamoxifen over a duration of up to 70 months. The vertical axis shows the proportion surviving, while the horizontal axis indicates months. The exemestane group (solid red line) demonstrates a higher survival proportion than the tamoxifen group (dashed blue line). The graph includes hazard ratio (HR 0.69, 95% CI 0.58-0.82) and p-value (0.00003) for the comparison.*
FDA Label Image

Edfb31df 8ec2 440f 84ca 5e86c10bbc46 03

Edfb31df 8ec2 440f 84ca 5e86c10bbc46 03
A line graph comparing the probability over time (in weeks) for two groups receiving Exemestane and Megestrol Acetate. The graph shows survival or event-free probability decreasing over a timeframe extending to approximately 140 weeks, with separate lines depicting each treatment group.*
FDA Label Image

Edfb31df 8ec2 440f 84ca 5e86c10bbc46 04

Edfb31df 8ec2 440f 84ca 5e86c10bbc46 04
Label for EXEMESTANE Tablets, USP 25 mg, oral tablet by Cipla USA Inc. The label states the package contains 30 tablets and includes storage instructions at 25°C (77°F) with permissible excursions. Manufactured by Cipla Ltd., Verna Goa, India, with commercial packing information for serial number, expiry, and lot number overprinting. Barcode and NDC 69097-316-02 are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.